Agreed. If a partner/buyer really wants leronlimab, the current SP (that is the current weak negotiation position) won't matter that much - if Allergan even paid a 10x premium for Tobira/cenicriviroc a few years back, after Tobira essentially failed, what will leronlimab be worth to an interested party, especially one that could tap a new market? If one reads the filings about that particular transaction, it becomes clear that the valuation was based on the science, indications and probabilities of success, not on the SP at that time. Therefore, the argument that BP couldn't justify to pay a hefty premium to its BOD/shareholders, is - in its generality - wrong. There are quite a few exceptions/counter-examples. And one could always do a CVR deal, where success in different indications trigger further payments...

Yet, I am still hopeful that after BLA submission and mono pivotal acceptance something huge will happen.